Anthony J. Recupero Sells 3,305 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) insider Anthony J. Recupero sold 3,305 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total transaction of $44,881.90. Following the completion of the sale, the insider now directly owns 233,412 shares of the company’s stock, valued at $3,169,734.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

SI-BONE Trading Up 6.0 %

Shares of SI-BONE stock traded up $0.83 on Friday, hitting $14.68. The stock had a trading volume of 419,623 shares, compared to its average volume of 296,744. The stock has a 50 day moving average of $14.95 and a 200 day moving average of $14.68. The firm has a market capitalization of $604.89 million, a P/E ratio of -13.47 and a beta of 1.22. SI-BONE, Inc. has a twelve month low of $11.76 and a twelve month high of $22.56. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.12 and a current ratio of 9.17.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.27%. The firm had revenue of $39.97 million for the quarter, compared to the consensus estimate of $38.95 million. During the same quarter in the previous year, the company earned ($0.30) EPS. Sell-side analysts expect that SI-BONE, Inc. will post -0.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC dropped their price target on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Morgan Stanley dropped their price objective on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Truist Financial reduced their target price on SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $23.00.

Institutional Investors Weigh In On SI-BONE

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its stake in SI-BONE by 1.5% in the second quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock valued at $768,000 after buying an additional 852 shares during the period. Arizona State Retirement System increased its position in SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after buying an additional 903 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of SI-BONE by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company’s stock worth $205,000 after purchasing an additional 1,105 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of SI-BONE by 7.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock valued at $336,000 after buying an additional 1,372 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in SI-BONE by 24.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after purchasing an additional 2,108 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.